Persones / Equip Humà

F. Xavier Palomer Tarridas

Buscador de publicacions

Publicacions

  • Barroso E, del Valle J, Porquet D, Vieira Santos AM, Salvadó L, Rodríguez-Rodríguez R, Gutiérrez P, Anglada-Huguet M, Alberch J, Camins A, Palomer FX, Pallàs M, Michalik L, Wahli W and Vazquez M.

    Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARß/d-null mice.

    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS . 1832(8): 1241-1248. Nº de cites: 36

    [doi:10.1016/j.bbadis.2013.03.006]

  • Salvadó L, Coll T, Gómez-Foix AM, Salmerón E, Barroso E, Palomer FX and Vazquez M.

    Oleate prevents saturated-fatty-acid-induced ER stress, inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism.

    Diabetologia . 56(6): 1372-1382. Nº de cites: 156

    [doi:10.1007/s00125-013-2867-3]

  • Serrano-Marco L, Chacón MR, Maymó-Masip E, Barroso E, Salvadó L, Wabitsch M, Garrido-Sánchez L, Tinahones FJ, Palomer FX, Vendrell J and Vazquez M.

    TNF-a inhibits PPARß/d activity and SIRT1 expression through NF-?B in human adipocytes.

    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS . 1821(9): 1177-1185. Nº de cites: 42

    [doi:10.1016/j.bbalip.2012.05.006]

  • Serrano-Marco L, Barroso E, El Kochairi I, Palomer FX, Michalik L, Wahli W and Vazquez M.

    The peroxisome proliferator-activated receptor (PPAR) ß/d agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.

    Diabetologia . 55(3): 743-751. Nº de cites: 54

    [doi:10.1007/s00125-011-2401-4]

  • Salvadó L, Serrano-Marco L, Barroso E, Palomer FX and Vazquez M.

    Targeting PPARß/d for the treatment of type 2 diabetes mellitus.

    EXPERT OPIN THER TAR . 16(2): 209-223. Nº de cites: 31

    [doi:10.1517/14728222.2012.658370]

  • Serrano-Marco L, Rodríguez-Calvo R, El Kochairi I, Palomer FX, Michalik L, Wahli W and Vazquez M.

    Activation of peroxisome proliferator-activated receptor-ß/-d (PPAR-ß/-d) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes.

    Diabetes . 60(7): 1990-1999. Nº de cites: 58

    [doi:10.2337/db10-0704]

  • Palomer FX, Álvarez-Guardia D, Davidson MM, Chan TO, Feldman AM and Vazquez M.

    The interplay between NF-kappaB and E2F1 coordinately regulates inflammation and metabolism in human cardiac cells.

    PLoS One . 6(5): . Nº de cites: 29

    [doi:10.1371/journal.pone.0019724]

  • Barroso E, Rodríguez-Calvo R, Serrano-Marco L, Astudillo AM, Balsinde J, Palomer FX and Vazquez M.

    The PPARß/d activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1a-Lipin 1-PPARa pathway leading to increased fatty acid oxidation.

    Endocrinology . 152(5): 1848-1859. Nº de cites: 120

    [doi:10.1210/en.2010-1468]

  • Barroso E, Eyre E, Palomer FX and Vazquez M.

    The peroxisome proliferator-activated receptor ß/d (PPARß/d) agonist GW501516 prevents TNF-a-induced NF-?B activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1.

    BIOCHEMICAL PHARMACOLOGY . 81(4): 534-543. Nº de cites: 51

    [doi:10.1016/j.bcp.2010.12.004]

  • Alvarez-Guardia D, Palomer FX, Coll T, Serrano L, Rodríguez-Calvo R, Davidson MM, Merlos M, El Kochairi I, Michalik L, Wahli W and Vazquez M.

    PPARß/d activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells.

    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS . 1811(2): 59-67. Nº de cites: 63

    [doi:10.1016/j.bbalip.2010.11.002]